Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cash from Discontinued Operations (2019 - 2021)

Historic Cash from Discontinued Operations for Cumberland Pharmaceuticals (CPIX) over the last 6 years, with Q4 2021 value amounting to $503318.0.

  • Cumberland Pharmaceuticals' Cash from Discontinued Operations fell 6277.66% to $503318.0 in Q4 2021 from the same period last year, while for Sep 2022 it was $503318.0, marking a year-over-year decrease of 8229.72%. This contributed to the annual value of $2.0 million for FY2021, which is 4331.48% down from last year.
  • As of Q4 2021, Cumberland Pharmaceuticals' Cash from Discontinued Operations stood at $503318.0, which was down 6277.66% from $496787.0 recorded in Q3 2021.
  • Over the past 5 years, Cumberland Pharmaceuticals' Cash from Discontinued Operations peaked at $3.0 million during Q4 2019, and registered a low of $38567.0 during Q2 2020.
  • For the 3-year period, Cumberland Pharmaceuticals' Cash from Discontinued Operations averaged around $918680.0, with its median value being $648983.5 (2020).
  • Its Cash from Discontinued Operations has fluctuated over the past 5 years, first plummeted by 9710.6% in 2020, then skyrocketed by 119335.18% in 2021.
  • Quarter analysis of 3 years shows Cumberland Pharmaceuticals' Cash from Discontinued Operations stood at $3.0 million in 2019, then plummeted by 55.34% to $1.4 million in 2020, then tumbled by 62.78% to $503318.0 in 2021.
  • Its Cash from Discontinued Operations was $503318.0 in Q4 2021, compared to $496787.0 in Q3 2021 and $498807.0 in Q2 2021.